Tobam Sells 4,022 Shares of The Clorox Company (NYSE:CLX)

Tobam decreased its stake in The Clorox Company (NYSE:CLX) by 8.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,736 shares of the company’s stock after selling 4,022 shares during the quarter. Clorox makes up about 2.6% of Tobam’s investment portfolio, making the stock its 8th largest position. Tobam’s holdings in Clorox were worth $6,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of CLX. Redwood Park Advisors LLC acquired a new position in Clorox in the fourth quarter worth $26,000. Millstone Evans Group LLC acquired a new position in Clorox in the fourth quarter worth $31,000. Wood Tarver Financial Group LLC acquired a new position in Clorox in the fourth quarter worth $31,000. Asset Planning Inc acquired a new position in Clorox in the fourth quarter worth $32,000. Finally, GKV Capital Management Co. Inc. acquired a new position in Clorox in the fourth quarter worth $32,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

Insider Transactions at Clorox

In related news, Director Pierre R. Breber purchased 4,000 shares of Clorox stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the transaction, the director now owns 4,000 shares of the company’s stock, valued at approximately $546,280. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.57% of the stock is owned by insiders.

Clorox Trading Up 0.8%

NYSE CLX opened at $127.25 on Friday. The Clorox Company has a 12 month low of $125.77 and a 12 month high of $171.37. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The company has a market capitalization of $15.68 billion, a PE ratio of 34.77, a P/E/G ratio of 2.62 and a beta of 0.54. The stock has a 50-day simple moving average of $135.18 and a 200 day simple moving average of $148.78.

Clorox (NYSE:CLX) last posted its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.12). Clorox had a net margin of 6.38% and a return on equity of 316.87%. The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same period in the previous year, the firm posted $1.71 earnings per share. The firm’s revenue was down 8.0% on a year-over-year basis. Research analysts forecast that The Clorox Company will post 7.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on CLX. Citigroup reduced their price objective on Clorox from $165.00 to $150.00 and set a “neutral” rating on the stock in a research note on Monday, April 14th. Morgan Stanley dropped their target price on Clorox from $165.00 to $150.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their target price on Clorox from $151.00 to $144.00 and set a “neutral” rating for the company in a research report on Tuesday, May 6th. Evercore ISI set a $140.00 target price on Clorox and gave the stock an “underperform” rating in a research report on Tuesday, May 6th. Finally, Wells Fargo & Company dropped their target price on Clorox from $145.00 to $142.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Clorox presently has a consensus rating of “Hold” and a consensus price target of $151.23.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.